View Older Stories View More Recent Stories
-
Nektar Therapeutics (NKTR) PT Raised to $178 at BTIG
-
Jefferies stays Buy on Nektar Therapeutics (NKTR) after Rezpeg data hits upside estimates, sees 10-30% stock move into Ph3
-
Oppenheimer Reiterates Outperform Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics reports positive 52-week data for alopecia areata drug trial
-
Nektar Therapeutics (NKTR) Halted, News Pending
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List
-
Oppenheimer on Nektar Therapeutics (NKTR): 'meaningful opportunities for biologics in AA'
-
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral
-
TD Cowen Starts Nektar Therapeutics (NKTR) at Buy
-
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer
-
Nektar Therapeutics (NKTR) Misses Q4 EPS by 178c
-
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Nektar Therapeutics, (NKTR)
-
Nektar Therapeutics (NKTR) PT Raised to $151 at BTIG
-
William Blair Upgrades Nektar Therapeutics (NKTR) to Outperform
-
Nektar reports positive REZOLVE-AD maintenance data for atopic dermatitis drug
-
Piper Sandler on Nektar Therapeutics (NKTR): 'We See a Substantial Opportunity Into These De-Risked Data'
-
Nektar Therapeutics (NKTR) PT Raised to $135 at H.C. Wainwright
-
Jefferies Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics (NKTR) PT Raised to $115 at Oppenheimer
-
Nektar reports mixed phase 2b results for alopecia areata drug
-
Nektar Therapeutics (NKTR) Halted, News Pending
-
Nektar Therapeutics (NKTR) PT Raised to $121 at Jefferies
-
Nektar Therapeutics enters $110 million equity distribution agreement
-
Oppenheimer Reiterates Outperform Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics (NKTR) Tops Q3 EPS by 185c
-
Nektar Therapeutics (NKTR) on Watch Following M&A Chatter
-
Nektar Therapeutics (NKTR) PT Raised to $105 at B.Riley
-
Nektar Therapeutics (NKTR) Strength Attributed to Rumor
-
Nektar Therapeutics (NKTR) PT Raised to $99 at Jefferies
-
Nektar presents positive Phase 2b atopic dermatitis trial results
-
Piper Sandler on Nektar Therapeutics (NKTR): 'A Perfect Opportunity to Own NKTR Ahead of Additional AD Data'
-
Analysts postive on Nektar opportunity after Sanofi data
-
Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
-
Nektar receives FDA fast track for alopecia areata treatment
-
Nektar Therapeutics (NKTR) Prices 4.26M Share Offering at $23.50/sh
-
Nektar Therapeutics (NKTR) Announces Proposed Public Offering
-
Nektar Therapeutics (NKTR) call put ratio 1 call to 1 put on 15K contracts as share price up 24%
-
Nektar Therapeutics (NKTR) PT Raised to $120 at H.C. Wainwright
-
Increasing unusual option volume: NKTR RGLS PAGS ASTL NTS HUYA PAYX EWY
-
Nektar Therapeutics (NKTR) PT Raised to $69 at Jefferies, 'data update gives us further confidence in Rezpeg's potential'
-
Nektar Therapeutics (NKTR) PT Raised to $100 at BTIG, 'We see NKTR as a "pound the table BUY"'
-
Increasing unusual option volume: NKTR PAGS GXO SFIX HUYA NTS RZLV MAIN COTY
-
Nektar Therapeutics (NKTR) to Resume Trading at 8 am
-
Nektar Therapeutics (NKTR): REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe AD
-
Nektar Therapeutics (NKTR) Halted, News Pending
-
Nektar Therapeutics (NKTR) to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June
-
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR)
-
Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c

